Autopsy report · NCT02538432

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

“PI No Longer at University of Maryland. Now at Fox Chase”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Maryland, Baltimore

Sponsor type

University, hospital or other

Conditions

Prostate Cancer; Non-Small Cell Lung Cancer; Breast Cancer

Interventions

RQ-00000007; Gemcitabine

Participants

0

Trials that died the same way

• Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis
  “PI no longer with the University” (71% match in meaning)
• Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion
  “PI has left the University” (71% match in meaning)
• Sensory Habituation in Autism Spectrum Disorders
  “PI no longer at institution.” (71% match in meaning)
• Protection From Cisplatin Ototoxicity by Lactated Ringers
  “PI left the university.” (69% match in meaning)
• Pulse Wave Analysis in Advanced Heart Failure
  “PI left University” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.